RhumbLine Advisers
RNA

RhumbLine Advisers’s Atrium Therapeutics RNA Stock Holding History

RhumbLine Advisers’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223K Buy
16,579
+1,626
+11% +$21.2K ﹤0.01% 3229
2026
Q1 		$200K Buy
+14,953
New +$210K ﹤0.01% 3119

Other funds holding RNA

SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

RhumbLine Advisers's RNA Position: Q2 2026 in Review

RhumbLine Advisers increased its Atrium Therapeutics (RNA) stake by 11% in Q2 2026, buying an estimated $21.2K and bringing the position to 16,579 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #3229.

RhumbLine Advisers first reported a position in RNA in Q1 2026 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold RNA as of Q2 2026.

  • RhumbLine Advisers held 16,579 shares of Atrium Therapeutics worth $223K as of Q2 2026.
  • RhumbLine Advisers bought 1,626 Atrium Therapeutics shares in Q2 2026, an estimated $21.2K.
  • Atrium Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3229 holding.
  • RhumbLine Advisers first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 155 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.